Posted by Michael Wonder on 04 Dec 2019
BridgeBio Pharma’s Origin Biosciences initiates rolling submission of new drug application with the U.S. FDA for BBP-870 for the treatment of MoCD type A
3 December 2019 - BridgeBio Pharma subsidiary Origin Biosciences has initiated a rolling submission of a NDA with the United States FDA for fosdenopterin (BBP-870/ORGN001) for the treatment of patients with molybdenum cofactor deficiency type A.
Currently, there are no approved therapies that alter the course of molybdenum cofactor deficiency (MoCD) Type A, which results in severe and irreversible neurological injury. Fosdenopterin, an investigative cPMP substrate replacement therapy, aims to reduce buildup of toxic sulfites and alleviate central nervous system symptoms in infants and children with MoCD Type A.
“Initiation of our rolling NDA submission is a significant milestone for our company and an important step in providing a therapy to patients and their families living with MoCD Type A,” said Origin Biosciences CEO Neil Kirby, Ph.D. “We look forward to making fosdenopterin available to infants and children with this devastating disease as soon as possible as they currently have no treatment options that target the disease at its source.”
